As of Wednesday close, TransCode Therapeutics Inc.’s (NASDAQ:RNAZ) stock was up $0.14, moving up 25.71 percent to $0.66. The average number of shares traded per day over the past five days has been 5,573,260 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.2400 fall in that time frame. In the last twenty days, the average volume was 1,444,320, while in the previous 50 days, it was 618,128.
Since last month, RNAZ stock retreated -60.00%. Shares of the company fell to $0.4998 on 09/19/23, the lowest level in the past month. A 52-week high of $31.00 was reached on 02/01/23 after having rallying from a 52-week low of $0.50. Since the beginning of this year, RNAZ’s stock price has dropped by -95.10% or -$12.8000, and marked a new high 6 times. However, the stock has declined by -97.87% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
RNAZ stock investors should be aware that TransCode Therapeutics Inc. (RNAZ) stock had its last reported insider trading activity 92 days ago on Jun 21. Dudley Robert Michael, the Chief Executive Officer of the company, purchased of 12,000 shares for $2.65 on Jun 21. It resulted in a $31,818 investment by the insider. Dudley Robert Michael added 6,607 shares at an average price of $2.55 on Jun 20. The insider now owns 70,262 shares following the transaction. On Jun 09, Chief Executive Officer Dudley Robert Michael bought 19,000 shares at $2.76 apiece. The transaction was valued at $52,440.
Financial Health
In the three months ended June 29, TransCode Therapeutics Inc.’s quick ratio stood at 1.40, while its current ratio was 1.40, showing that the company is able to pay off its debt.
While analysts expected TransCode Therapeutics Inc. to report -$3.39 quarterly earnings, the actual figure was -$3.29 per share, beating the consensus estimate by 2.90%. The liabilities of TransCode Therapeutics Inc. were 3.79 million at the end of its most recent quarter ended June 29, and its total debt was $0.66 million. The value of shareholders’ equity is $2.03 million.
Technical Picture
This quick technical analysis looks at TransCode Therapeutics Inc.’s (RNAZ) price momentum. With a historical volatility rate of 171.93%, the RSI 9-day stood at 24.59% on 20 September.
With respect to its five-day moving average, the current TransCode Therapeutics Inc. price is down by -26.67% percent or -$0.2400. At present, RNAZ shares trade -60.48% below its 20-day simple moving average and -90.13% percent below its 100-day simple moving average. However, the stock is currently trading approximately -74.32% below its SMA50 and -91.75% below its SMA200.
Stochastic coefficient K was 5.45% and Stochastic coefficient D was 3.51%, while ATR was 0.1829. Given the Stochastic reading of 13.25% for the 14-day period, the RSI (14) reading has been calculated as 23.20%. As of today, the MACD Oscillator reading stands at -0.1805, while the 14-day reading stands at -0.4038.
Analyst Ratings
TransCode Therapeutics Inc. (RNAZ) has been rated Buy by analysts. According to 0 brokerage firms, RNAZ is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate TransCode Therapeutics Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $12.00, the current consensus forecast for the stock is $12.00 – $12.00. Based on these forecasts, analysts predict TransCode Therapeutics Inc. (RNAZ) will achieve an average price target of $12.00.
